{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:03:45Z","timestamp":1780617825440,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404930"],"award-info":[{"award-number":["82404930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Bayu Young Scholar Program","award":["S2023027"],"award-info":[{"award-number":["S2023027"]}]},{"name":"Chongqing Bayu Qihuang Young Scholar Program","award":["Chongqing Bayu Qihuang Young Scholar Program"],"award-info":[{"award-number":["Chongqing Bayu Qihuang Young Scholar Program"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08129-7","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:55:30Z","timestamp":1776826530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gypenosides inhibit melanoma proliferation, migration and enhance the anti-tumor immunity of CD8+ T cells via ETV5\/PD-L1 signaling"],"prefix":"10.1186","volume":"24","author":[{"given":"Yue","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changpeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-5641","authenticated-orcid":false,"given":"Guobing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"8129_CR1","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dr\u00e9no B, Eggermont AMM, Fargnoli MC, Forsea A-M, H\u00f6ller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebb\u00e9 C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. Eur J Cancer. 2025;215:115152. https:\/\/doi.org\/10.1016\/j.ejca.2024.115152.","journal-title":"Eur J Cancer"},{"key":"8129_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F, Jemal A, Alteri R, Ganz PA, Siegel RL. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin. 2025;75:308\u201340. https:\/\/doi.org\/10.3322\/caac.70011.","journal-title":"CA Cancer J Clin"},{"key":"8129_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/s1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su S-C, Krepler C, Ibrahim N. Long, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"key":"8129_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2018.3964","volume":"155","author":"R Ghiasvand","year":"2019","unstructured":"Ghiasvand R, Robsahm TE, Green AC, Rueegg CS, Weiderpass E, Lund E, Veier\u00f8d MB. Association of Phenotypic Characteristics and UV Radiation Exposure With Risk of Melanoma on Different Body Sites. JAMA Dermatology. 2019;155:39. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3964.","journal-title":"JAMA Dermatology"},{"key":"8129_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040\u201359. https:\/\/doi.org\/10.1016\/j.ejca.2005.03.034.","journal-title":"Eur J Cancer"},{"key":"8129_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2023.11.070","volume":"91","author":"P Funchain","year":"2024","unstructured":"Funchain P, Ni Y, Heald B, Bungo B, Arbesman M, Behera TR, McCormick S, Song JM, Kennedy LB, Nielsen SM, Esplin ED, Nizialek E, Ko J, Diaz-Montero CM, Gastman B, Stratigos AJ, Artomov M, Tsao H, Arbesman J. Germline cancer susceptibility in individuals with melanoma. J Am Acad Dermatol. 2024;91:265\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.070.","journal-title":"J Am Acad Dermatol"},{"key":"8129_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","volume":"87","author":"AW Kubica","year":"2012","unstructured":"Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012;87:991\u20131003. https:\/\/doi.org\/10.1016\/j.mayocp.2012.04.018.","journal-title":"Mayo Clin Proc"},{"key":"8129_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jama.1992.03490100112037","volume":"268","author":"LA Goldsmith","year":"1992","unstructured":"Goldsmith LA. Diagnosis and Treatment of Early Melanoma. JAMA. 1992;268:1314. https:\/\/doi.org\/10.1001\/jama.1992.03490100112037.","journal-title":"JAMA"},{"key":"8129_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0140-6736(21)01206-x","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(21)01206-x.","journal-title":"Lancet"},{"key":"8129_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(23)00821-8.","journal-title":"Lancet"},{"key":"8129_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-025-06687-w","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Liu Y, Zhao D, Shan D, Guo C, Jia L. Engineering macrophages for targeted immunotherapy and drug delivery in melanoma. J Transl Med. 2025;23:998. https:\/\/doi.org\/10.1186\/s12967-025-06687-w.","journal-title":"J Transl Med"},{"key":"8129_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"8129_CR13","doi-asserted-by":"publisher","first-page":"1631273","DOI":"10.3389\/fimmu.2025.1631273","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Xie Y, Wang T, Liu Y, Tian Y, Hua Y. Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab. Front Immunol. 2025;16:1631273. https:\/\/doi.org\/10.3389\/fimmu.2025.1631273.","journal-title":"Front Immunol"},{"key":"8129_CR14","doi-asserted-by":"publisher","first-page":"114506","DOI":"10.1016\/j.jep.2021.114506","volume":"281","author":"YS Qi","year":"2021","unstructured":"Qi YS, Xie JB, Xie P, Duan Y, Ling YQ, Gu YL, Piao XL. Uncovering the anti-NSCLC effects and mechanisms of gypenosides by metabolomics and network pharmacology analysis. J Ethnopharmacol. 2021;281:114506. https:\/\/doi.org\/10.1016\/j.jep.2021.114506.","journal-title":"J Ethnopharmacol"},{"key":"8129_CR15","doi-asserted-by":"publisher","first-page":"114017","DOI":"10.1016\/j.jep.2021.114017","volume":"273","author":"ML Zu","year":"2021","unstructured":"Zu ML, Duan Y, Xie JB, Qi YS, Xie P, Borjigidai A, Piao XL. Gypenoside LI arrests the cell cycle of breast cancer in G0\/G1 phase by down-regulating E2F1. J Ethnopharmacol. 2021;273:114017. https:\/\/doi.org\/10.1016\/j.jep.2021.114017.","journal-title":"J Ethnopharmacol"},{"key":"8129_CR16","doi-asserted-by":"publisher","first-page":"1243353","DOI":"10.3389\/fphar.2024.1243353","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu H, Lai W, Wang Q, Zhou Q, Zhang R, Zhao Y. Gypenoside induces apoptosis by inhibiting the PI3K\/AKT\/mTOR pathway and enhances T-cell antitumor immunity by inhibiting PD-L1 in gastric cancer. Front Pharmacol. 2024;15:1243353. https:\/\/doi.org\/10.3389\/fphar.2024.1243353.","journal-title":"Front Pharmacol"},{"key":"8129_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/0960327113497771","volume":"33","author":"H Yan","year":"2014","unstructured":"Yan H, Wang X, Wang Y, Wang P, Xiao Y. Antiproliferation and anti-migration induced by gypenosides in human colon cancer SW620 and esophageal cancer Eca-109 cells. Hum Exp Toxicol. 2014;33:522\u201333. https:\/\/doi.org\/10.1177\/0960327113497771.","journal-title":"Hum Exp Toxicol"},{"key":"8129_CR18","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.gendis.2023.05.026","volume":"11","author":"H Wang","year":"2024","unstructured":"Wang H, Li Z, Wang Q, Lin W, Zhou Z, Mu X, Jiang Y, Lu S, Chen S, Lu Z. Gypenosides ameliorate morphine-induced immunosuppression with an increased proportion of thymic T lymphocyte subsets and are involved in the regulation of the cAMP-CREM\/CREB-IL-2 pathway. Genes Dis. 2024;11:101049. https:\/\/doi.org\/10.1016\/j.gendis.2023.05.026.","journal-title":"Genes Dis"},{"key":"8129_CR19","doi-asserted-by":"publisher","first-page":"107539","DOI":"10.1016\/j.bioorg.2024.107539","volume":"150","author":"MY Xiao","year":"2024","unstructured":"Xiao MY, Pei WJ, Li S, Li FF, Xie P, Luo HT, Hyun Yoo H, Piao XL. Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response. Bioorg Chem. 2024;150:107539. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107539.","journal-title":"Bioorg Chem"},{"key":"8129_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-023-00909-3","volume":"30","author":"Y Wei","year":"2023","unstructured":"Wei Y, Han S, Wen J, Liao J, Liang J, Yu J, Chen X, Xiang S, Huang Z, Zhang B. E26 transformation-specific transcription variant 5 in development and cancer: modification, regulation and function. J Biomed Sci. 2023;30:17. https:\/\/doi.org\/10.1186\/s12929-023-00909-3.","journal-title":"J Biomed Sci"},{"key":"8129_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-025-3098-4","author":"F Kuang","year":"2025","unstructured":"Kuang F, Hu Z, Huangfu L, Yan G, Dhiman S, Chen W, Li Z. ETV5 upregulates PD-L1 transcription to inhibit cytotoxic CD8(+) T cell proliferation in colorectal cancer. Sci China Life Sci. 2025. https:\/\/doi.org\/10.1007\/s11427-025-3098-4.","journal-title":"Sci China Life Sci"},{"key":"8129_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/gutjnl-2024-333944","volume":"74","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Huang W, Hu D, Jiang J, Zhang J, Wu Z, Wen J, Luo X, Wang Y, Sun M, Li S, Wang Y, Liu D, Chen X, Zhang B, Liang H, Li Y, Liu B, Wang S, Xu X, Nie Y, Wu K, Fan D, Xia L. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression. Gut. 2025;74:1137\u201349. https:\/\/doi.org\/10.1136\/gutjnl-2024-333944.","journal-title":"Gut"},{"key":"8129_CR23","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1158\/0008-5472.CAN-06-4487","volume":"67","author":"M Monge","year":"2007","unstructured":"Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J, Quiles M, Arbos MA, Garcia A, Castellvi J, Llaurado M, Rigau M, Alazzouzi H, Xercavins J, Alameda F, Reventos J, Abal M. ERM\/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res. 2007;67:6753\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4487.","journal-title":"Cancer Res"},{"key":"8129_CR24","doi-asserted-by":"publisher","first-page":"e2307242","DOI":"10.1002\/advs.202307242","volume":"11","author":"J Wen","year":"2024","unstructured":"Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, Chu L, Li H, Han S, Liao J, Chen Z, Liu Y, Liu Q, Ding Z, Liang H, Gan L, Chen X, Huang Z, Zhang B. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5\/PD-L1\/VEGFA Axis. Adv Sci (Weinh). 2024;11:e2307242. https:\/\/doi.org\/10.1002\/advs.202307242.","journal-title":"Adv Sci (Weinh)"},{"key":"8129_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32:30\u201344. https:\/\/doi.org\/10.1016\/j.tcb.2021.07.001.","journal-title":"Trends Cell Biol"},{"key":"8129_CR26","doi-asserted-by":"publisher","unstructured":"Watt FM, Fujiwara H. Cell-extracellular matrix interactions in normal and diseased skin. Cold Spring Harb Perspect Biol. 2011;3. https:\/\/doi.org\/10.1101\/cshperspect.a005124.","DOI":"10.1101\/cshperspect.a005124"},{"key":"8129_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/14756366.2016.1161620","volume":"31","author":"A Jablonska-Trypuc","year":"2016","unstructured":"Jablonska-Trypuc A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31:177\u201383. https:\/\/doi.org\/10.3109\/14756366.2016.1161620.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"8129_CR28","doi-asserted-by":"publisher","unstructured":"Niland S, Riscanevo AX, Eble JA. Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2021;23. https:\/\/doi.org\/10.3390\/ijms23010146.","DOI":"10.3390\/ijms23010146"},{"key":"8129_CR29","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-19-1668","volume":"81","author":"L Huang","year":"2021","unstructured":"Huang L, Zhai Y, La J, Lui JW, Moore SPG, Little EC, Xiao S, Haresi AJ, Brem C, Bhawan J, Lang D. Targeting Pan-ETS Factors Inhibits Melanoma Progression. Cancer Res. 2021;81:2071\u201385. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1668.","journal-title":"Cancer Res"},{"key":"8129_CR30","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/odi.14724","volume":"30","author":"S Yu","year":"2024","unstructured":"Yu S, Ma Z, Chen T, Wang H, Yao Q, Li J, Cheng J. ETV5 facilitates tumor progression in head-neck squamous cell carcinoma. Oral Dis. 2024;30:2004\u201317. https:\/\/doi.org\/10.1111\/odi.14724.","journal-title":"Oral Dis"},{"key":"8129_CR31","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/1541-7786.MCR-11-0449","volume":"10","author":"M Llaurado","year":"2012","unstructured":"Llaurado M, Majem B, Castellvi J, Cabrera S, Gil-Moreno A, Reventos J, Ruiz A. Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer. Mol Cancer Res. 2012;10:914\u201324. https:\/\/doi.org\/10.1158\/1541-7786.MCR-11-0449.","journal-title":"Mol Cancer Res"},{"key":"8129_CR32","doi-asserted-by":"publisher","first-page":"612784","DOI":"10.3389\/fimmu.2020.612784","volume":"11","author":"H Qu","year":"2020","unstructured":"Qu H, Zhao H, Zhang X, Liu Y, Li F, Sun L, Song Z. Integrated Analysis of the ETS Family in Melanoma Reveals a Regulatory Role of ETV7 in the Immune Microenvironment. Front Immunol. 2020;11:612784. https:\/\/doi.org\/10.3389\/fimmu.2020.612784.","journal-title":"Front Immunol"},{"key":"8129_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"key":"8129_CR34","doi-asserted-by":"publisher","first-page":"1705946","DOI":"10.3389\/fphar.2025.1705946","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Chen Y, Wang R, Cao B, Deng T, Han J, Yang M. Gypenosides, a promising phytochemical triterpenoid: research progress on its pharmacological activity and mechanism. Front Pharmacol. 2025;16:1705946. https:\/\/doi.org\/10.3389\/fphar.2025.1705946.","journal-title":"Front Pharmacol"},{"key":"8129_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11373-006-9076-8","volume":"13","author":"TH Huang","year":"2006","unstructured":"Huang TH, Li Y, Razmovski-Naumovski V, Tran VH, Li GQ, Duke CC, Roufogalis BD. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. J Biomed Sci. 2006;13:535\u201348. https:\/\/doi.org\/10.1007\/s11373-006-9076-8.","journal-title":"J Biomed Sci"},{"key":"8129_CR36","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/jcmm.12546","volume":"19","author":"JS Liu","year":"2015","unstructured":"Liu JS, Chiang TH, Wang JS, Lin LJ, Chao WC, Inbaraj BS, Lu JF, Chen BH. Induction of p53-independent growth inhibition in lung carcinoma cell A549 by gypenosides. J Cell Mol Med. 2015;19:1697\u2013709. https:\/\/doi.org\/10.1111\/jcmm.12546.","journal-title":"J Cell Mol Med"},{"key":"8129_CR37","doi-asserted-by":"publisher","first-page":"820639","DOI":"10.3389\/fphar.2022.820639","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Li X, Xie J, Lv C, Lian F, Zhang S, Duan Y, Zeng Y, Piao X. Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell Carcinoma via Regulation of the MAPK and Arachidonic Acid Metabolism Pathways. Front Pharmacol. 2022;13:820639. https:\/\/doi.org\/10.3389\/fphar.2022.820639.","journal-title":"Front Pharmacol"},{"key":"8129_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ni.2587","volume":"14","author":"V Jojic","year":"2013","unstructured":"Jojic V, Shay T, Sylvia K, Zuk O, Sun X, Kang J, Regev A, Koller D, Immunological Genome Project C, Best AJ, Knell J, Goldrath A, Joic V, Koller D, Shay T, Regev A, Cohen N, Brennan P, Brenner M, Kim F, Rao TN, Wagers A, Heng T, Ericson J, Rothamel K, Ortiz-Lopez A, Mathis D, Benoist C, Bezman NA, Sun JC, Min-Oo G, Kim CC, Lanier LL, Miller J, Brown B, Merad M, Gautier EL, Jakubzick C, Randolph GJ, Monach P, Blair DA, Dustin ML, Shinton SA, Hardy RR, Laidlaw D, Collins J, Gazit R, Rossi DJ, Malhotra N, Sylvia K, Kang J, Kreslavsky T, Fletcher A, Elpek K, Bellemarte-Pelletier A, Malhotra D, Turley S. Identification of transcriptional regulators in the mouse immune system. Nat Immunol. 2013;14:633\u201343. https:\/\/doi.org\/10.1038\/ni.2587.","journal-title":"Nat Immunol"},{"key":"8129_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41419-020-03111-7","volume":"11","author":"H Feng","year":"2020","unstructured":"Feng H, Liu K, Shen X, Liang J, Wang C, Qiu W, Cheng X, Zhao R. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer. Cell Death Dis. 2020;11:916. https:\/\/doi.org\/10.1038\/s41419-020-03111-7.","journal-title":"Cell Death Dis"},{"key":"8129_CR40","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1089\/thy.2018.0314","volume":"29","author":"M Bullock","year":"2019","unstructured":"Bullock M, Lim G, Zhu Y, Aberg H, Kurdyukov S, Clifton-Bligh R. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer. Thyroid. 2019;29:1623\u201333. https:\/\/doi.org\/10.1089\/thy.2018.0314.","journal-title":"Thyroid"},{"key":"8129_CR41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.7150\/ijms.71892","volume":"19","author":"MC Sun","year":"2022","unstructured":"Sun MC, Fang K, Li ZX, Chu Y, Xu AP, Zhao ZY, Leng ZY, Zhang YW, Zhang ZH, Zhang L, Chen T, Xu MD. ETV5 overexpression promotes progression of esophageal squamous cell carcinoma by upregulating SKA1 and TRPV2. Int J Med Sci. 2022;19:1072\u201381. https:\/\/doi.org\/10.7150\/ijms.71892.","journal-title":"Int J Med Sci"},{"key":"8129_CR42","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1038\/onc.2011.632","volume":"31","author":"E Colas","year":"2012","unstructured":"Colas E, Muinelo-Romay L, Alonso-Alconada L, Llaurado M, Monge M, Barbazan J, Gonzalez M, Schoumacher M, Pedrola N, Ertekin T, Devis L, Ruiz A, Castellvi J, Doll A, Gil-Moreno A, Vazquez-Levin M, Lapyckyj L, Lopez-Lopez R, Robine S, Friederich E, Castro M, Reventos J, Vignjevic D, Abal M. ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene. 2012;31:4778\u201388. https:\/\/doi.org\/10.1038\/onc.2011.632.","journal-title":"Oncogene"},{"key":"8129_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jhep.2025.01.020","volume":"83","author":"X Xue","year":"2025","unstructured":"Xue X, Liu R, Cai Y, Gong L, Fan G, Wu J, Li X, Li X. Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4. J Hepatol. 2025;83:52\u201369. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.020.","journal-title":"J Hepatol"},{"key":"8129_CR44","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32:4235\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.026.","journal-title":"Mol Ther"},{"key":"8129_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/emmm.201100165","volume":"3","author":"K Karwacz","year":"2011","unstructured":"Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8\u2009+\u2009T cells. EMBO Mol Med. 2011;3:581\u201392. https:\/\/doi.org\/10.1002\/emmm.201100165.","journal-title":"EMBO Mol Med"},{"key":"8129_CR46","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425\u201334. https:\/\/doi.org\/10.1038\/s41590-019-0512-0.","journal-title":"Nat Immunol"},{"key":"8129_CR47","doi-asserted-by":"publisher","unstructured":"Wu S, Anand N, Guo Z, Li M, Santiago Figueroa M, Jung L, Kelly S, Franses JW. Bridging Immune Evasion and Vascular Dynamics for Novel Therapeutic Frontiers in Hepatocellular Carcinoma. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17111860.","DOI":"10.3390\/cancers17111860"},{"key":"8129_CR48","doi-asserted-by":"publisher","unstructured":"Anand N, Peh KH, Kolesar JM. Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24032858.","DOI":"10.3390\/ijms24032858"},{"key":"8129_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, Feng Y, Wang Y, Li Y, Liu B, Huang W, Xia L. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.036.","journal-title":"J Hepatol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08129-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:37:25Z","timestamp":1780616245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08129-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8129"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08129-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments complied with relevant regulations of national laboratory animal welfare ethics. Animal experimentation and the corresponding protocol were approved by the Laboratory Animal Welfare and Fthics Committee of the Army Medical University (Ethical Number: AMUWEC20255370).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that there are no conflicts of this manuscript. We confirm that we have read and understand the Phytomedicine Conflict of Interest Policy. We guarantee that the results and interpretations reported in the manuscript are original and have not been plagiarized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"735"}}